Boston Scientific Signs Definitive Agreement to Sell BTG Specialty Pharmaceuticals Business. Click to read release..

How BTG Specialty Pharmaceuticals is Responding to the COVID-19 Pandemic

Our priority is to protect and aid the health and safety of our employees, our customers and their patients. That means ensuring our vital products are available when needed. It also means finding new and creative ways to support the frontline healthcare providers working tirelessly to address the COVID-19 pandemic.

Supporting our customers:

Our teams are supporting healthcare providers with training and in-service sessions delivered by web-based videoconference and shipping supporting materials directly to hospitals. There are also extensive resources available on,, and

Reliably supplying our products:

We recognize the special attention being paid to the supply of vital products. We are confident in our robust supply chain and our ability to continue providing quality rescue medicines to meet the needs of customers and patients.

  • There is currently enough CroFab® within the United States to supply all of our customers for the remainder of 2020 (based on typical seasonal rates of use).
  • CroFab® cartons are now shipped with a 5-year shelf life and we have a replacement policy for any expired product (visit for details).
  • There is at least enough Voraxaze® and DigiFab® in supply channels to meet the demand of US hospitals for the remainder of 2020.

Protecting our product:

We have performed a thorough technical assessment of the COVID-19 virus (SARS-CoV-2) and concluded there is no risk to our CroFab® and DigiFab® products. Our process includes low pH hold for viral inactivation and viral removal by nanofiltration. All processing is performed in high classification clean rooms. For more details on this assessment contact our medical affairs team.

Protecting our employees:

We take seriously our responsibility to protect the health and safety of our employees. Those who can perform their job functions from home have been working remotely with flexible work arrangements. Extra precautions, including increased cleaning measures, social distancing protocols, temperature monitoring, and health reporting are in place for the essential employees who remain at our manufacturing sites to ensure we can continue to produce and supply our products safely and effectively.

Employee assistance resources are available to support the physical, mental and financial health of our global workforce.

Supporting communities:

To date our parent company, Boston Scientific, has committed $1.3 million to aid COVID-19 relief efforts. This includes donations of supplies to local hospitals, including protective masks, goggles, gloves and other protective items to meet the urgent needs of healthcare providers, as well as direct financial contributions to local community organizations to support children, families and the most vulnerable.

It will take time for nations and local communities to manage through and fully recover from the wide-ranging impact of this complex situation. We are committed to supporting our stakeholders through this pandemic so that together we can emerge from this challenging time stronger. 

US-CRF-2000122 May 2020